LENZ THERAPEUTICS, INC. Selling, General and Administrative Expense
LENZ THERAPEUTICS, INC. (LENZ) reported Selling, General and Administrative Expense of $39.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $39.38M, a 207.74% increase year-over-year.
- LENZ THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $44.96M, a 304.57% increase year-over-year.
- LENZ THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $39.63M, a 323.57% increase year-over-year.
- LENZ THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $27.60M, a 324.95% increase year-over-year.
- LENZ THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $91.14M, a 216.35% increase from fiscal 2024.
- LENZ THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $28.81M, a 122.89% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2023 was $12.93M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.38M 10-Q · filed 2026-08-11 | $84.34M 10-Q · filed 2026-08-11 | $123.97M derived: sum of 3 quarters · filed 2026-08-11 | $151.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $44.96M 10-Q · filed 2026-05-11 | $84.59M derived: sum of 2 quarters · filed 2026-05-11 | $112.19M derived: sum of 3 quarters · filed 2026-05-11 | $124.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $39.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $67.23M derived: sum of 2 quarters · filed 2026-03-24 | $80.03M derived: sum of 3 quarters · filed 2026-08-11 | $91.14M 10-K · filed 2026-03-24 |
| 2025-09-30 | $27.60M 10-Q · filed 2025-11-05 | $40.39M derived: sum of 2 quarters · filed 2026-08-11 | $51.51M 10-Q · filed 2025-11-05 | $60.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $12.80M 10-Q · filed 2026-08-11 | $23.91M 10-Q · filed 2026-08-11 | $33.27M derived: sum of 3 quarters · filed 2026-08-11 | $39.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $11.11M 10-Q · filed 2026-05-11 | $20.47M derived: sum of 2 quarters · filed 2026-05-11 | $26.96M derived: sum of 3 quarters · filed 2026-05-11 | $34.37M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $9.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $15.85M derived: sum of 2 quarters · filed 2026-03-24 | $23.26M derived: sum of 3 quarters · filed 2026-03-24 | $28.81M 10-K · filed 2026-03-24 |
| 2024-09-30 | $6.49M 10-Q · filed 2025-11-05 | $13.90M derived: sum of 2 quarters · filed 2025-11-05 | $19.45M 10-Q · filed 2025-11-05 | $24.91M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $7.41M 10-Q · filed 2025-07-30 | $12.96M 10-Q · filed 2025-07-30 | $18.41M derived: sum of 3 quarters · filed 2025-07-30 | $21.27M derived: sum of 4 quarters · filed 2025-07-30 |
| 2024-03-31 | $5.55M 10-Q · filed 2025-05-07 | $11.00M derived: sum of 2 quarters · filed 2025-05-07 | $13.87M derived: sum of 3 quarters · filed 2025-05-07 | $16.18M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $8.31M derived: sum of 2 quarters · filed 2025-03-19 | $10.63M derived: sum of 3 quarters · filed 2025-03-19 | $12.93M 10-K · filed 2025-03-19 |
| 2023-09-30 | $2.86M 10-Q · filed 2024-11-06 | $5.18M derived: sum of 2 quarters · filed 2024-11-06 | $7.47M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $2.32M 10-Q · filed 2024-08-14 | $4.61M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $2.29M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |